{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:49:58Z","timestamp":1790696998945,"version":"4.1.0"},"reference-count":108,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.clml.2022.01.016","type":"journal-article","created":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T02:29:40Z","timestamp":1644028180000},"page":"e507-e520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Thrombocytopenia in Patients With Myelofibrosis: Pathogenesis, Prevalence, Prognostic Impact, and Treatment"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3243-8205","authenticated-orcid":false,"given":"Dahniel","family":"Sastow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4719-7192","authenticated-orcid":false,"given":"Douglas","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.01.016_bib0001","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2141.2012.09179.x","article-title":"Guideline for the diagnosis and management of myelofibrosis","volume":"158","author":"Reilly","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.01.016_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/HS9.0000000000000001","article-title":"Myelofibrosis-related anemia: current and emerging therapeutic strategies","volume":"1","author":"Naymagon","year":"2017","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2022.01.016_bib0003","doi-asserted-by":"crossref","unstructured":"Tefferi A, Lasho TL, Jimma T, et\u00a0al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Paper presented at: Mayo Clinic Proceedings 2012.","DOI":"10.4016\/38289.01"},{"key":"10.1016\/j.clml.2022.01.016_bib0004","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2141.1990.tb02609.x","article-title":"Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients","volume":"75","author":"Visani","year":"1990","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.01.016_bib0005","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00005792-198311000-00002","article-title":"The syndrome of idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survival","volume":"62","author":"Varki","year":"1983","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clml.2022.01.016_bib0006","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.016_bib0007","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kr\u00f6ger","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.016_bib0008","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1586\/17474086.2016.1154452","article-title":"Alleviating anemia and thrombocytopenia in myelofibrosis patients","volume":"9","author":"Cervantes","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2022.01.016_bib0009","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1080\/10428194.2020.1728752","article-title":"Thrombocytopenia in patients with myelofibrosis: management options in the era of JAK inhibitor therapy","volume":"61","author":"Benevolo","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.01.016_bib0010","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/17474086.2018.1500456","article-title":"Pacritinib to treat myelofibrosis patients with thrombocytopenia","volume":"11","author":"Tremblay","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2022.01.016_bib0011","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2006-12-064626","article-title":"Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis","volume":"110","author":"Ciurea","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.016_bib0012","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2141.2007.06807.x","article-title":"Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres","volume":"139","author":"Kuter","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.01.016_bib0013","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.exphem.2014.10.013","article-title":"CXC motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients","volume":"43","author":"Wang","year":"2015","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2022.01.016_bib0014","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.3109\/10428194.2013.769537","article-title":"Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis","volume":"54","author":"Nazha","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.01.016_bib0015","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1172\/JCI105380","article-title":"Pooling of platelets in the spleen: role in the pathogenesis of","volume":"45","author":"Aster","year":"1966","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2022.01.016_bib0016","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","article-title":"Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients","volume":"95","author":"Tefferi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.016_bib0017","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10428194.2013.794269","article-title":"Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation","volume":"55","author":"Santos","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.01.016_bib0018","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1600-0609.1984.tb02189.x","article-title":"Platelet-associated IgG and IgM in myelofibrosis","volume":"32","author":"Hasselbalch","year":"1984","journal-title":"Scand J Haematol"},{"key":"10.1016\/j.clml.2022.01.016_bib0019","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.016_bib0020","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1002\/stem.1711","article-title":"Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells","volume":"32","author":"Akada","year":"2014","journal-title":"Stem Cells"},{"key":"10.1016\/j.clml.2022.01.016_bib0021","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/blood-2014-03-559815","article-title":"JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation","volume":"124","author":"Besancenot","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.016_bib0022","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.01.016_bib0023","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.01.016_bib0024","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2022.01.016_bib0025","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2013.286","article-title":"U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2 V617F and normal karyotype","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.016_bib0026","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.016_bib0027","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.016_bib0028","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/ejh.13005","article-title":"Significance of thrombocytopenia in patients with primary and postessential thrombocythemia\/polycythemia vera myelofibrosis","volume":"100","author":"Masarova","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.01.016_bib0029","doi-asserted-by":"crossref","unstructured":"Alhuraiji A, Masarova L, Bose P, et\u00a0al. Clinical features and outcome of patients with poor-prognosis myelofibrosis based on platelet count< 50 x 109\/L: a single-center experience in 1100 myelofibrosis patients. In: American Society of Clinical Oncology; 2016.","DOI":"10.1200\/JCO.2016.34.15_suppl.7068"},{"key":"10.1016\/j.clml.2022.01.016_bib0030","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.3324\/haematol.2013.101733","article-title":"The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis","volume":"99","author":"Hern\u00e1ndez-Boluda","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.01.016_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106338","article-title":"Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported","volume":"91","author":"Masarova","year":"2020","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2022.01.016_bib0032","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.016_bib0033","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1200\/JCO.2009.22.8833","article-title":"Dynamic model for predicting death within 12 months in patients with primary or post\u2013polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"27","author":"Tam","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.016_bib0034","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/bjh.14601","article-title":"Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia","volume":"181","author":"Hern\u00e1ndez-Boluda","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.01.016_bib0035","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.leukres.2017.10.002","article-title":"Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs","volume":"63","author":"Scotch","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2022.01.016_bib0036","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.016_bib0037","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.016_bib0038","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.016_bib0039","doi-asserted-by":"crossref","first-page":"45","DOI":"10.12703\/P6-45","article-title":"Management of thrombocytopenia","volume":"6","author":"Izak","year":"2014","journal-title":"F1000Prime Rep"},{"key":"10.1016\/j.clml.2022.01.016_bib0040","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2141.2005.05524.x","article-title":"Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients","volume":"129","author":"Cervantes","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.01.016_bib0041","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00277-015-2435-7","article-title":"Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results","volume":"94","author":"Cervantes","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2022.01.016_bib0042","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJM198702263160903","article-title":"Effect of danazol in immune thrombocytopenic purpura","volume":"316","author":"Schreiber","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.01.016_bib0043","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/rheumatology\/36.10.1095","article-title":"Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases","volume":"36","author":"Blanco","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.clml.2022.01.016_bib0044","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/1076029615622002","article-title":"The effect of danazol in primary immune thrombocytopenia: an analysis of a large cohort from a single center in China","volume":"22","author":"Liu","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.clml.2022.01.016_bib0045","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ajh.10209","article-title":"Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome","volume":"71","author":"Chan","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.01.016_bib0046","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.leukres.2017.06.005","article-title":"Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis","volume":"60","author":"Gowin","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2022.01.016_bib0047","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2217\/fon-2020-1048","article-title":"MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic","volume":"17","author":"Verstovsek","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2022.01.016_bib0048","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00277-020-04069-4","article-title":"Modern management of splenomegaly in patients with myelofibrosis","volume":"99","author":"Tremblay","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2022.01.016_bib0049","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1365-2141.2002.03443.x","article-title":"Thalidomide treatment in myelofibrosis with myeloid metaplasia","volume":"117","author":"Elliott","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.01.016_bib0050","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1080\/1042819021000040008","article-title":"Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies","volume":"43","author":"Barosi","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.01.016_bib0051","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","article-title":"A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia","volume":"101","author":"Mesa","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.016_bib0052","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3324\/haematol.12416","article-title":"Low-dose thalidomide in myelofibrosis","volume":"93","author":"Weinkove","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.01.016_bib0053","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2004.08.160","article-title":"Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial","volume":"22","author":"Marchetti","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.016_bib0054","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/cncr.21827","article-title":"Thalidomide therapy for myelofibrosis with myeloid metaplasia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"issue":"S1","key":"10.1016\/j.clml.2022.01.016_bib0055","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/01.HS9.0000564132.52005.a0","article-title":"PS1467 early results of a phase II study of combined ruxolitinib and thalidomide in patients with myelofibrosis","volume":"3","author":"Rampal","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2022.01.016_bib0056","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1182\/blood-2006-02-004572","article-title":"Lenalidomide therapy in myelofibrosis with myeloid metaplasia","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.016_bib0057","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1200\/JCO.2009.22.6548","article-title":"Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.016_bib0058","first-page":"1058","article-title":"Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.01.016_bib0059","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ajh.22233","article-title":"Long-term outcome of pomalidomide therapy in myelofibrosis","volume":"87","author":"Begna","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.01.016_bib0060","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/leu.2016.300","article-title":"A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence","volume":"31","author":"Tefferi","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.016_bib0061","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/leu.2016.299","article-title":"Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis","volume":"31","author":"Schlenk","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.016_bib0062","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3109\/10428194.2014.924121","article-title":"Two cases of myelofibrosis with severe thrombocytopenia and symptomatology successfully treated with combination of pomalidomide and ruxolitinib","volume":"56","author":"Andrei","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.01.016_bib0063","series-title":"Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia","author":"Stegelmann","year":"2019"},{"key":"10.1016\/j.clml.2022.01.016_bib0064","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2012-04-425512","article-title":"Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study","volume":"121","author":"Saleh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.016_bib0065","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1056\/NEJMoa073255","article-title":"Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C","volume":"357","author":"McHutchison","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.01.016_bib0066","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","article-title":"Eltrombopag added to standard immunosuppression for aplastic anemia","volume":"376","author":"Townsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2022.01.016_bib0067","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.3324\/haematol.2020.260125","article-title":"The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis","volume":"106","author":"Shoukier","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.01.016_bib0068","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2022.01.016_bib0069","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.016_bib0070","first-page":"13","article-title":"Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes","volume":"7","author":"Verstovsek","year":"2014","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clml.2022.01.016_bib0071","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-6-81","article-title":"Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts","volume":"6","author":"Talpaz","year":"2013","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2022.01.016_bib0072","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","article-title":"Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial","volume":"101","author":"Al-Ali","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.01.016_bib0073","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3324\/haematol.2018.204602","article-title":"EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis","volume":"104","author":"Vannucchi","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.01.016_bib0074","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/bloodadvances.2019000954","article-title":"Fedratinib in myelofibrosis","volume":"4","author":"Mullally","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.01.016_bib0075","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.01.016_bib0076","doi-asserted-by":"crossref","unstructured":"Harrison CN, Schaap N, Vannucchi AM, et\u00a0al. Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): a reanalysis of the JAKARTA-2 study. In: American Society of Clinical Oncology; 2019.","DOI":"10.1200\/JCO.2019.37.15_suppl.7057"},{"key":"10.1016\/j.clml.2022.01.016_bib0077","series-title":"Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients With Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, Who Were Either Ruxolitinib-Na\u00efve or Were Previously Treated With Ruxolitinib","author":"Harrison","year":"2019"},{"key":"10.1016\/j.clml.2022.01.016_bib0078","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.2147\/OTT.S267001","article-title":"Clinical utility of fedratinib in myelofibrosis","volume":"14","author":"Waksal","year":"2021","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clml.2022.01.016_bib0079","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/JEP.S110702","article-title":"Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor","volume":"8","author":"Singer","year":"2016","journal-title":"J Exp Pharmacol"},{"key":"10.1016\/j.clml.2022.01.016_bib0080","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2217\/fon-2017-0494","article-title":"Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia","volume":"14","author":"Diaz","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2022.01.016_bib0081","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.01.016_bib0082","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2022.01.016_bib0083","article-title":"Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia","author":"Verstovsek","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.01.016_bib0084","series-title":"Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib","author":"Gerds","year":"2019"},{"key":"10.1016\/j.clml.2022.01.016_bib0085","doi-asserted-by":"crossref","first-page":"S352","DOI":"10.1016\/S2152-2650(21)01815-2","article-title":"MPN-038: PACIFICA: a randomized, controlled phase 3 study of pacritinib versus physician's choice in patients with primary or secondary myelofibrosis and severe thrombocytopenia","volume":"21","author":"Mascarenhas","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.01.016_bib0086","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.016_bib0087","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"Simplify-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor\u2013na\u00efve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.016_bib0088","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.01.016_bib0089","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-018-0067-6","article-title":"Momelotinib therapy for myelofibrosis: a 7-year follow-up","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.01.016_bib0090","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1080\/14656566.2019.1657093","article-title":"Momelotinib for the treatment of myelofibrosis","volume":"20","author":"Xu","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clml.2022.01.016_bib0091","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3324\/haematol.2016.151126","article-title":"Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor","volume":"102","author":"Mascarenhas","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.01.016_bib0092","doi-asserted-by":"crossref","unstructured":"Kuykendall AT, Burke L, Lakshminarayanan M, Colucci P. Abstract CT236: a two-part phase 2 study of itacitinib immediate release in patients with primary or secondary myelofibrosis who have received prior ruxolitinib and\/or fedratinib monotherapy. In: AACR; 2021.","DOI":"10.1158\/1538-7445.AM2021-CT236"},{"key":"10.1016\/j.clml.2022.01.016_bib0093","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"114","author":"Kr\u00f6ger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.016_bib0094","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.016_bib0095","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/leu.2008.91","article-title":"A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia\/polycythemia vera myelofibrosis","volume":"22","author":"Quintas-Cardama","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.016_bib0096","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood.V112.11.2809.2809","article-title":"Phase II trial of low dose, subcutaneous decitabine in myelofibrosis","volume":"112","author":"Odenike","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.016_bib0097","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-04-846626","article-title":"A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis","volume":"132","author":"Masarova","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.016_bib0098","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/bloodadvances.2020002119","article-title":"Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase","volume":"4","author":"Mascarenhas","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.01.016_bib0099","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.leukres.2015.06.001","article-title":"Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic\/acute myeloid leukemia phase","volume":"39","author":"Badar","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2022.01.016_bib0100","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000506146","article-title":"Clinical benefit derived from decitabine therapy for advanced phases of myeloproliferative neoplasms","volume":"144","author":"Zhou","year":"2021","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2022.01.016_bib0101","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.hoc.2020.12.003","article-title":"Current clinical investigations in myelofibrosis","volume":"35","author":"Venugopal","year":"2021","journal-title":"Hematol Oncol Clin"},{"key":"10.1016\/j.clml.2022.01.016_bib0102","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1084\/jem.20160283","article-title":"Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis","volume":"213","author":"Verstovsek","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.clml.2022.01.016_bib0103","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2018-99-115362","article-title":"PRM-151 in myelofibrosis: efficacy and safety in an open label extension study","volume":"132","author":"Verstovsek","year":"2018","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.clml.2022.01.016_bib0104","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/01.HS9.0000561592.51072.9b","article-title":"S828 A randomized, double blind phase 2 study of 3 different doses of PRM-151 in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib","volume":"3","author":"Verstovsek","year":"2019","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2022.01.016_bib0105","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3390\/cells10051034","article-title":"Next generation therapeutics for the treatment of myelofibrosis","volume":"10","author":"Tremblay","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.clml.2022.01.016_bib0106","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1182\/blood-2012-06-439661","article-title":"Characterization of the TGF-\u03b21 signaling abnormalities in the Gata1low mouse model of myelofibrosis","volume":"121","author":"Zingariello","year":"2013","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2022.01.016_bib0107","doi-asserted-by":"crossref","first-page":"e145651","DOI":"10.1172\/jci.insight.145651","article-title":"TGF-\u03b21 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis","volume":"6","author":"Varricchio","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.clml.2022.01.016_bib0108","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-148995","article-title":"Treatment of myelofibrosis patients with the TGF-\u03b2 1\/3 inhibitor AVID200 (MPN-RC 118) induces a profound effect on platelet production","volume":"138","author":"Mascarenhas","year":"2021","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022000325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022000325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T10:00:32Z","timestamp":1682935232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022000325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":108,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2152265022000325"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.01.016","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombocytopenia in Patients With Myelofibrosis: Pathogenesis, Prevalence, Prognostic Impact, and Treatment","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}